Topic Menu
► Topic MenuTopic Editors


Host Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development
Topic Information
Dear Colleagues,
SARS-CoV-2 continues its frenzied race towards unknown evolutive goals that are difficult to predict. To date, we have experienced four pandemic waves—with a fifth on the rise—accounting for more than half a billion people infected and more than six million dead. These numbers are impressive and stress the need for appropriate responses. Though several strategies, from quick vaccine development and administration to the design and availability of antivirals including monoclonal antibodies, have already been employed, we are still experiencing an unjustified number of fatalities. In the last two years, the scientific community implemented huge research efforts that massively impacted our understanding of the viral pathogenesis mechanism related to the SARS-CoV-2 infection and the COVID-19 syndrome. Using fundamental and breakthrough research techniques to tackle the pandemic, we deepened our knowledge of the mechanisms underlying host–microbe interactions, leading to development of effective vaccines and treatments. This Topic welcomes innovative, high-quality research articles, as well as review articles with original opinions focused on the host response to the SARS-CoV-2 infection in terms of its implications for diagnosis, treatment and innovative vaccine development. We seek contributions that report the latest advances, challenges and methodologies for tackling COVID-19. Investigations on in silico models built on the pandemic prevalence and incidence are also welcome. Submissions should clarify the substantive improvements on work that has already been published, accepted for publication, or submitted in parallel to other conferences or journals.
Dr. Fabrizio Angius
Prof. Dr. Meng Ling Moi
Topic Editors
Keywords
- SARS-CoV-2
- vaccines
- ACE2
- COVID-19
- diagnosis
- treatment
- antibodies
- monoclonal antibodies
- recombinant protein
Participating Journals
Journal Name | Impact Factor | CiteScore | Launched Year | First Decision (median) | APC |
---|---|---|---|---|---|
![]()
Antibodies
|
3.0 | 7.1 | 2012 | 22.8 Days | CHF 1800 |
![]()
COVID
|
- | - | 2021 | 20.3 Days | CHF 1000 |
![]()
Pathogens
|
3.3 | 6.4 | 2012 | 15.3 Days | CHF 2200 |
![]()
Vaccines
|
5.2 | 8.9 | 2013 | 18.6 Days | CHF 2700 |
![]()
Viruses
|
3.8 | 7.3 | 2009 | 17.1 Days | CHF 2600 |
Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.
MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:
- Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
- Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
- Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
- Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
- Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.